Virtual Interaction With Experts: Exploring Novel Therapeutics in Acute Myeloid Leukemia

Join us for this live, online, IME-certified symposium at EHA 2020 featuring discussion of patient case studies and review of key recent clinical trial data by renowned clinical experts on the treatment of AML. Sign up for this Webinar now!

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “Virtual Interaction With Experts: Exploring Novel Therapeutics in Acute Myeloid Leukemia” that was originally scheduled as an in-person symposium in Frankfurt, Germany. Due to the global impact of COVID-19, EHA organizers have decided to host the EHA Annual Meeting in a virtual format. 

As such, this live symposium will also now be held as a virtual live Webinar. Please note that the Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To register, click the link below and once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


Experts Discuss the Latest Advances in Acute Myeloid Leukemia

Program Overview and Introduction
Selecting Therapy for Challenging AML Patients
New and Novel Advances in AML Therapeutics—Future Targeted Approaches
Other targets for antibody-directed therapy
Final Thoughts and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Guillermo Garcia Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Richard Dillon, MD

Clinical Senior Lecturer
Department of Medical & Molecular Genetics
King's Hospital, London
Consultant Haematologist
Department of Haematology
Guy's Hospital
London, United Kingdom

This educational activity is not certified for CME/CE credit.

Goal Statement
The goal of this activity is to improve the competence of learners to understand emerging clinical data and promising agents that can optimize the care of their patients with AML.

Target Audience
This program is intended for medical oncologists and other healthcare providers who care for patients with acute myeloid leukemia globally.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan evidence-based therapeutic strategies or clinical trial enrollment for older patients, those with preexisting comorbidities, and/or those unfit for intensive chemotherapy
  • Evaluate the available clinical data defining the role of epigenetic regulation in the management of AML
  • Assess the available evidence on investigational immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
  • Manage treatment-related toxicities associated with novel therapeutics in AML


This educational activity is not certified for CME/CE credit.